SCHEMBL19468435

SCHEMBL19468435

COc1cc(C)cc(OC)c1C(O)c1ccco1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.38
MEN1 O00255 3/20 0.38
POLB P06746 2/20 0.38
HPGD P15428 2/20 0.38
ALDH1A1 P00352 5/20 0.38
LMNA P02545 3/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
ACHE P22303 2/20 0.37
PKM P14618 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN7 P35236 1/20 0.36
BLM P54132 1/20 0.36
ESR2 Q92731 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MAPT P10636 2/20 0.35
HSD17B10 Q99714 1/20 0.35
CFB P00751 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19468426 0.81 MAPT (0.37) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL432528 0.80 KMT2A (0.40) KMT2AMEN1POLBALDH1A1GAA
SCHEMBL16269441 0.77 LMNA (0.34) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL14993582 0.75 KMT2A (0.39) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL18231192 0.75 CNR2 (0.49) KMT2AMEN1ALDH1A1LMNAACHE
SCHEMBL4601881 0.74 SMN1; SMN2 (0.46) POLBHPGDALDH1A1LMNAHTT
SCHEMBL20299216 0.71 KMT2A (0.41) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL16281711 0.70 KMT2A (0.38) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL1653635 0.70 KMT2A (0.38) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL10187529 0.70 KMT2A (0.38) KMT2AMEN1POLBHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112142586-B Ketone or oxime compounds and herbicides 日产化学株式会社 2023-05-09 CN disclosed
EP-4053097-A1 KETONE COMPOUND AS HERBICIDE Corteva Agriscience LLC (US) 2022-09-07 EP disclosed
EP-3235799-B1 OXIME COMPOUND AND HERBICIDE NISSAN CHEMICAL CORP (JP) 2022-02-23 EP disclosed
US-11000033-B2 Ketone or oxime compound, and herbicide NISSAN CHEMICAL CORPORATION (JP) 2021-05-11 US disclosed
US-20200077650-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE NISSAN CHEMICAL CORPORATION (JP) 2020-03-12 US disclosed
US-20190053488-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE NISSAN CHEMICAL CORPORATION (JP) 2019-02-21 US disclosed
US-10136640-B2 Ketone or oxime compound, and herbicide NISSAN CHEMICAL CORPORATION (JP) 2018-11-27 US disclosed
US-20170347647-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-12-07 US disclosed
EP-3235799-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE Nissan Chemical Industries, Ltd. (JP) 2017-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11000033-B2 Ketone or oxime compound, and herbicide OR10J3, CYP1B1, CBR3 KMT2A 357/4885MEN1 3295/4885POLB 1846/4885
US-10136640-B2 Ketone or oxime compound, and herbicide OR10J3, CYP1B1, CBR3 KMT2A 357/4885MEN1 3264/4885POLB 1859/4885
US-20200077650-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE OR10J3, CYP1B1, CBR3 KMT2A 357/4885MEN1 3295/4885POLB 1846/4885
US-20190053488-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE OR10J3, CYP1B1, CBR3 KMT2A 357/4885MEN1 3264/4885POLB 1859/4885
US-20170347647-A1 KETONE OR OXIME COMPOUND, AND HERBICIDE OR10J3, CYP1B1, CBR3 KMT2A 357/4885MEN1 3264/4885POLB 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.